Current Situation of Health Care in Women With HBV or HCV Infection
Not yet recruiting
- Conditions
- HBVHCV
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 2500
- Registration Number
- NCT06579313
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
Early Phase 1
Recruiting
- Conditions
- Pancreatic NeoplasmsOther Solid Tumors
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT06577532
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
Phase 2
Not yet recruiting
- Conditions
- Lymphoma
- Interventions
- Drug: Selinexor, anti-PD-1 antibody and P-GemOx
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06573151
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC
Phase 1
Recruiting
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06572514
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Real-World Study on Extranodal Lymphoma
Not yet recruiting
- Conditions
- Lymphoma, Non-HodgkinExtranodal LymphomaLymphomaLymphoma, B-CellDiffuse Large B Cell Lymphoma
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 5000
- Registration Number
- NCT06573099
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
Phase 2
Not yet recruiting
- Conditions
- Lymphoma, Extranodal NK-T-Cell
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06573138
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
Phase 2
Not yet recruiting
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- Combination Product: SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06573398
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
Not Applicable
Recruiting
- Conditions
- Liver NeoplasmsMetastasisBreast Neoplasms
- Interventions
- Device: Multi-mode tumor treatment systemDevice: Radiofrequency ablation therapeutic apparatus
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06567353
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
Phase 2
Not yet recruiting
- Conditions
- Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06567366
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China
Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke
Not Applicable
- Conditions
- Stroke, Ischemic
- Interventions
- Other: Control groupOther: Intervention group
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06551727
- Locations
- 🇨🇳
Ruijin North Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath